North America Leads Today, Asia Pacific to Record Fastest GrowthThe global high throughput screening market, valued at ...

In July 2025, Mersana made a payment of approximately $17.9 million to satisfy in full its indebtedness and obligations under the company’s previous loan and security agreement. The company continues ...

Revenue (GAAP) for Q2 2025 was $3.1 million, missing the $6.2 million estimate but up from $2.3 million in the same period of 2024. Cost-cutting efforts led to lower research and administrative ...

More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data fro ...

Hexyl Acetate Market UK CAGR rises from 2.5% to 3.8% by 2035, driven by natural fragrances, premium skincare, body sprays, and innovative f ...

Thermo Fisher Scientific Inc. maintains global leadership through an extensive portfolio of automated systems, screening instruments, and consumables, underpinned by 3% annual R&D investment and ...

No revenue reported as development-stage programs advanced in key clinical trials. These 10 stocks could mint the next wave of millionaires › PDS Biotechnology (NASDAQ:PDSB), a clinical-stage ...

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the ...

Bullish option flow detected in Merck (MRK) with 12,315 calls trading, 1.4x expected, and implied vol increasing over 1 point to 26.72%. Sep-25 85 ...

Gain insights from Mersana Therapeutics' Q2 2025 earnings call. Highlights include Emi-Le advancements in TNBC, $15M milestone, and a $77M cash position.